Why is the measurement of efficiency in health care so important, but equally challenging? And why is it especially so in primary care? This blog provides an overview of these well-known issues, and offers a glimpse into the results of a new OHE analysis of approaches to measure efficiency in primary care and recommendations for future research.
Case studies explored more and less successful practices when delivering healthcare across four priority areas (screening, disease management and standardised patient pathways, rational use of medicines and healthcare associated infections). Results were used to simulate cost-savings and patient outcomes that could potentially be realised with improvements in efficiency across the European Union of 27 countries and the United Kingdom.
In a recently published OHE Consulting Report, we report the long-term return on investment (ROI) per £1 spent on various vaccination programmes from the perspective of the UK government. In this blog, we discuss how discounting affects the estimated long-term value of vaccination and, thus, decision-makers’ investment decisions.
On the occasion of Adam Wagstaff’s death, Professor Tony Culyer reflects on his vast legacy to health economics, from Tony’s perspective of having been Adam’s PhD supervisor as well as a friend and collaborator.
Adrian Towse presented at the Monash Malaysia Health Economics Forum 2019 on three related topics: health system financing in Malaysia; pharmaceutical price regulation and competition in Malaysia; and the potential for using real world evidence to improve the efficiency of the Malaysian health system.
OHE has been awarded a 3-year research grant by the Health Foundation’s Efficiency Research Programme to define an accurate measure of labour productivity in primary care and to identify its determinants, including workforce skill mix, technology and patient characteristics.
The Trump Administration proposed an International Pricing Index for reimbursing physician-administered Medicare drugs. A conservative thought leader proposed a different basket of 'market-oriented' countries. These differ markedly from the U.S. Their governments have a central role in medicines purchase, in contrast to U.S. reliance on private markets.
A new OHE Consulting Report describes the current status of real-world data in Japan, including core legislation and governance arrangements. The authors sought to understand how real-world data is accessed or generated and used to produce or generate real-world evidence, and to see whether use is aligned with international standards.